Adverse events964

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 964

Type	Event	Organ system	Group	Affected	At risk
other	Edema: Limb	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	83	362
other	Edema: Limb	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	76	355
other	Hemoglobin	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	67	362
other	Hemoglobin	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	53	355
other	INR	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	19	362
other	INR	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	19	355
other	Leukocytes	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	16	362
other	Leukocytes	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	21	355
other	Platelets	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	44	362
other	Platelets	Blood and lymphatic system disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	51	355
other	Hypertension	Cardiac disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	71	362
other	Hypertension	Cardiac disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	86	355
other	Anorexia	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	156	362
other	Anorexia	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	135	355
other	Ascites	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	77	362
other	Ascites	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	91	355
other	Constipation	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	51	362
other	Constipation	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	76	355
other	Dehydration	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)	21	362
other	Dehydration	Gastrointestinal disorders	Sorafenib (Nexavar, BAY43-9006) + Placebo	8	355

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00901901/events

API reference For AI assistants

Adverse events964

Sources 3

Read this list from software.